Armenian Translation

Anacor finds novel mechanism for lead anti-fungal medication tests.

Anacor finds novel mechanism for lead anti-fungal medication, AN2690 Anacor Pharmaceuticals, a held pharmaceutical company privately, has announced that the journal Technology shall publish results of research that details how AN2690, the company’s lead clinical applicant, kills fungal cells by interfering with synthesis of a specific protein necessary for fungal growth tests . This original mechanism of action, made possible by the business’s boron-based chemistry, may also confirm useful in developing brand-new classes of therapeutic agents such as antibiotics. In the June 22 problem of the journal The research results will be published. ‘Understanding the way in which AN2690 stops fungal infections has given us a wealth of info about how to fashion antimicrobial medications, including other anti-fungal substances and systemic antibiotics,’ said Dickon Alley, Ph.D., mind of discovery biology at Anacor and an author of the Science paper.